China biotech company GluBio raises $22m
China and US-based GluBio Therapeutics, which develops targeted protein degradation (TPD) drugs, has raised an extended Series A round of USD22m led by Qiming Venture Partners.
Lilly Asia Ventures and Kaitai Capital also took part. It brings total funding to nearly USD 90m since the company's inception in March 2021. Protein degraders tackle tough drug targets by taking over...
More on Greater China
Latest News
Bain seeks delisting of Chindata within three years of listing
Bain Capital has submitted a USD 2.9bn take-private bid for Chindata Group, a largely China-focused data centre operator that it assembled through a buy-and-build and took public in October 2020.
Japan's J-Star buys freight forwarding company
Japan’s J-Star has acquired local freight forwarding business Japan Trust Holdings for an undisclosed sum as part of a transportation services consolidation play.
Ex-Eaton Asia head targets asset management, GP stakes
Chris Lerner, formerly of Eaton Partners and MSA Capital, has established an asset management operation that will ultimately raise an Asian fund-of-funds and teamed up with US-based Bonaccord Capital Partners to expand its GP stakes business into the...
Northstar's managing partner to become CEO of GoTo
Patrick Walujo, a co-founder and managing partner of Northstar Group, has been appointed group CEO of Indonesian super app GoTo, with the Southeast Asia-focused private equity firm telling LPs it expects minimal impact to day-to-day business.